UBS AM’s BeOne Medicines Ltd ONC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $635K | Buy |
2,137
+761
| +55% | +$246K | ﹤0.01% | 2487 |
|
|
2025
Q4 | $418K | Buy |
+1,376
| New | +$450K | ﹤0.01% | 2357 |
|
|
2025
Q3 | – | Sell |
-4,236
| Closed | -$1.03M | – | 2668 |
|
|
2025
Q2 | $1.03M | Buy |
4,236
+250
| +6% | +$61.3K | ﹤0.01% | 2378 |
|
|
2025
Q1 | $1.08M | Buy |
3,986
+650
| +19% | +$152K | ﹤0.01% | 2268 |
|
|
2024
Q4 | $616K | Sell |
3,336
-450
| -12% | -$91.9K | ﹤0.01% | 2518 |
|
|
2024
Q3 | $850K | Sell |
3,786
-1,021
| -21% | -$184K | ﹤0.01% | 2466 |
|
|
2024
Q2 | $686K | Buy |
4,807
+2,418
| +101% | +$373K | ﹤0.01% | 2541 |
|
|
2024
Q1 | $374K | Sell |
2,389
-1,597
| -40% | -$257K | ﹤0.01% | 2355 |
|
|
2023
Q4 | $719K | Buy |
3,986
+753
| +23% | +$136K | ﹤0.01% | 2193 |
|
|
2023
Q3 | $582K | Sell |
3,233
-405
| -11% | -$80.1K | ﹤0.01% | 2235 |
|
|
2023
Q2 | $784K | Hold |
3,638
| – | – | ﹤0.01% | 2113 |
|
|
2023
Q1 | $784K | Sell |
3,638
-9,485
| -72% | -$2.28M | ﹤0.01% | 2113 |
|
|
2022
Q4 | $2.89M | Sell |
13,123
-177,994
| -93% | -$32.6M | ﹤0.01% | 1372 |
|
|
2022
Q3 | $25.8M | Buy |
191,117
+3,112
| +2% | +$534K | 0.01% | 703 |
|
|
2022
Q2 | $30.4M | Buy |
188,005
+3,134
| +2% | +$490K | 0.02% | 649 |
|
|
2022
Q1 | $34.9M | Buy |
184,871
+3,349
| +2% | +$712K | 0.01% | 699 |
|
|
2021
Q4 | $49.2M | Buy |
181,522
+898
| +0.5% | +$303K | 0.02% | 663 |
|
|
2021
Q3 | $65.6M | Buy |
180,624
+1,542
| +0.9% | +$504K | 0.03% | 561 |
|
|
2021
Q2 | $61.5M | Sell |
179,082
-11,932
| -6% | -$3.95M | 0.03% | 589 |
|
|
2021
Q1 | $66.5M | Buy |
191,014
+4,145
| +2% | +$1.37M | 0.03% | 546 |
|
|
2020
Q4 | $48.3M | Buy |
186,869
+56,898
| +44% | +$15.7M | 0.02% | 625 |
|
|
2020
Q3 | $37.2M | Buy |
129,971
+3,914
| +3% | +$920K | 0.02% | 607 |
|
|
2020
Q2 | $23.7M | Sell |
126,057
-1,294
| -1% | -$211K | 0.01% | 695 |
|
|
2020
Q1 | $15.7M | Buy |
127,351
+7,678
| +6% | +$1.2M | 0.01% | 742 |
|
|
2019
Q4 | $19.8M | Buy |
119,673
+5,257
| +5% | +$873K | 0.01% | 780 |
|
|
2019
Q3 | $14M | Sell |
114,416
-1,672
| -1% | -$222K | 0.01% | 855 |
|
|
2019
Q2 | $14.4M | Buy |
116,088
+4,980
| +4% | +$632K | 0.01% | 846 |
|
|
2019
Q1 | $14.7M | Buy |
111,108
+7,826
| +8% | +$1.06M | 0.01% | 827 |
|
|
2018
Q4 | $14.5M | Buy |
103,282
+98,082
| +1,886% | +$13M | 0.01% | 771 |
|
|
2018
Q3 | $896K | Buy |
5,200
+5,070
| +3,900% | +$853K | ﹤0.01% | 1853 |
|
|
2018
Q2 | $20K | Buy |
+130
| New | +$23.2K | ﹤0.01% | 2650 |
|
Other funds holding ONC
BBA
HA
UBS AM's ONC Position: Q1 2026 in Review
UBS AM increased its BeOne Medicines Ltd (ONC) stake by 55% in Q1 2026, buying an estimated $246K and bringing the position to 2,137 shares worth $635K. The position accounts for ﹤0.01% of the portfolio, ranked #2487.
UBS AM first reported a position in ONC in Q2 2018 and has held it in 31 quarters since. The position peaked at $66.5M in Q1 2021. 281 funds tracked by Wall St. Rank hold ONC as of Q1 2026.
- UBS AM held 2,137 shares of BeOne Medicines Ltd worth $635K as of Q1 2026.
- UBS AM bought 761 BeOne Medicines Ltd shares in Q1 2026, an estimated $246K.
- BeOne Medicines Ltd made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #2487 holding.
- UBS AM first reported a position in BeOne Medicines Ltd in Q2 2018 and has held it in 31 quarters since.
- UBS AM's BeOne Medicines Ltd position peaked at $66.5M in Q1 2021.
- 281 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.
Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.